Sanofi $SNY Shares Sold by Zimmer Partners LP

Key Points

• Zimmer Partners LP reduced its stake in Sanofi by 25.9%, selling 126,700 shares during the first quarter, and now holds 361,600 shares worth approximately $20 million.
• Several hedge funds, including Price T Rowe Associates and Federated Hermes, have increased their investments in Sanofi, reflecting a broader trend of institutional investors modifying their positions in the stock.
• Sanofi's recent earnings report showed a miss on earnings per share, reporting $0.90 compared to an expected $0.96, but revenue exceeded estimates at $11.34 billion.

Zimmer Partners LP lessened its position in Sanofi (NASDAQ:SNY - Free Report) by 25.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 361,600 shares of the company's stock after selling 126,700 shares during the quarter. Zimmer Partners LP's holdings in Sanofi were worth $20,054,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in SNY. Accent Capital Management LLC bought a new stake in shares of Sanofi in the 1st quarter worth about $29,000. Eastern Bank increased its stake in Sanofi by 121.0% in the 1st quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after buying an additional 300 shares during the period. Banque Transatlantique SA purchased a new position in Sanofi in the 1st quarter worth about $33,000. Golden State Wealth Management LLC increased its stake in Sanofi by 619.3% in the 1st quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after buying an additional 545 shares during the period. Finally, Brentview Investment Management LLC purchased a new position in Sanofi in the 1st quarter worth about $42,000. Institutional investors own 14.04% of the company's stock.

Sanofi Trading Down 1.3%

Sanofi stock traded down $0.62 during midday trading on Friday, hitting $47.03. 2,728,115 shares of the stock were exchanged, compared to its average volume of 2,604,652. Sanofi has a fifty-two week low of $44.73 and a fifty-two week high of $60.12. The stock has a market capitalization of $115.48 billion, a price-to-earnings ratio of 11.31, a PEG ratio of 1.12 and a beta of 0.51. The stock's 50-day simple moving average is $48.68 and its 200 day simple moving average is $51.21. The company has a current ratio of 1.27, a quick ratio of 0.94 and a debt-to-equity ratio of 0.19.

Sanofi (NASDAQ:SNY - Get Free Report) last announced its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). The company had revenue of $11.34 billion for the quarter, compared to analysts' expectations of $9.91 billion. Sanofi had a return on equity of 16.86% and a net margin of 21.47%.The company's quarterly revenue was down 7.0% compared to the same quarter last year. During the same period last year, the business earned $1.73 EPS. On average, equities analysts anticipate that Sanofi will post 4.36 EPS for the current year.

Wall Street Analyst Weigh In

Several research analysts recently commented on SNY shares. Barclays reaffirmed an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Guggenheim reiterated a "buy" rating on shares of Sanofi in a research note on Tuesday, June 3rd. JPMorgan Chase & Co. upgraded shares of Sanofi from a "neutral" rating to an "overweight" rating in a research note on Friday, August 8th. Morgan Stanley upgraded shares of Sanofi from an "equal weight" rating to an "overweight" rating and upped their price target for the company from $56.00 to $58.00 in a research note on Monday. Finally, Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "hold" rating to a "buy" rating in a research note on Tuesday, September 2nd. Three research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $62.67.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.